Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis
Stroke · 13.11.2026
DOI: 10.1161/strokeaha.125.053981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stroke, online erschienen am 13.11.2026. Verfasst von Mukul Sharma und 35 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada (M.S., L.X., J.W.E., M.C., A.S.). Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0–12.0) and 14.0 days (interquartile range, 10.0–20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33–5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33–4.48]), female sex (HR, 1.78 [95% CI, 1.00–3.16]), and age (HR per year, 1.04 [95% CI, 1.00–1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64–4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76–3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20–3.01]), and age (HR per year, 1.06 [95% CI, 1.03–1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02329327.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada (M.S., L.X., J.W.E., M.C., A.S.).
- Department of Haematological Medicine, Guys and St. Thomas' Hospitals NHS Foundation Trust, King's College, London, United Kingdom (A.T.C.).
- Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada (A.M.D.).
- Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.).
- Department of Clinical Sciences Lund, Neurology, Lund University, Sweden (A.G.L.).
- Department of Neurology, Skåne University Hospital, Lund, Sweden (A.G.L.).
ORCID-Profile: Mukul Sharma, John W Eikelboom, Alexander T Cohen, Andrew M Demchuk, Anna Członkowska, Arne G Lindgren, Carlos A Molina, Daniel Bereczki, Danilo Toni, David J Seiffge, David Tanne, Else Charlotte Sandset, Georgios Tsivgoulis, Hanne Christensen, Jan Beyer-Westendorf, Jonathan M Coutinho, Peter Verhamme, Pierre Amarenco, Risto O Roine, Robert Mikulik, Robin Lemmens, Roland Veltkamp, Saskia Middeldorp, Truman John Milling, Sven Poli, C Michael Gibson, Deborah M Siegal, Per Ladenvall, Ashkan Shoamanesh
Zitieren
APA
Sharma, M., Xu, L., Eikelboom, J. W., Cohen, A. T., Demchuk, A. M., Członkowska, A., Lindgren, A. G., Molina, C. A., Bereczki, D., Toni, D., Seiffge, D. J., Tanne, D., Sandset, E. C., Tsivgoulis, G., Christensen, H., Beyer-Westendorf, J., Coutinho, J. M., Crowther, M., Verhamme, P., …, & ANNEXa-4 and ANNEXa-I Investigators (2026). Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis. Stroke. https://doi.org/10.1161/strokeaha.125.053981
Vancouver
Sharma M, Xu L, Eikelboom JW, Cohen AT, Demchuk AM, Członkowska A, et al. Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis. Stroke. 2026. doi:10.1161/strokeaha.125.053981
BibTeX
@article{Sharma2026,
author = {Sharma, Mukul and Xu, Lizhen and Eikelboom, John W and Cohen, Alexander T and Demchuk, Andrew M and Członkowska, Anna and Lindgren, Arne G and Molina, Carlos A and Bereczki, Daniel and Toni, Danilo and Seiffge, David J and Tanne, David and Sandset, Else Charlotte and Tsivgoulis, Georgios and Christensen, Hanne and Beyer-Westendorf, Jan and Coutinho, Jonathan M and Crowther, Mark and Verhamme, Peter and Amarenco, Pierre and Roine, Risto O and Mikulik, Robert and Lemmens, Robin and Veltkamp, Roland and Middeldorp, Saskia and Milling, Truman John and Poli, Sven and Gibson, C Michael and Siegal, Deborah M and Knutsson, Mikael and Falkenberg, Cecilia and Narayan, Rohit and Kurlyandskaya, Raisa and Ladenvall, Per and Shoamanesh, Ashkan and ANNEXa-4 and ANNEXa-I Investigators, ANNEXa-4 and ANNEXa-I Investigators},
title = {Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis},
journal = {Stroke},
year = {2026},
doi = {10.1161/strokeaha.125.053981}
}
EUVIMED